Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1010 vaccine variations in healthy adults
NCT05868382Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- May 2023
- Primary completion
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mRNA-1010 in influenza, sponsored by Moderna Inc. Primary endpoints: Number of Participants With Solicited Local and Systemic Adverse Reactions, Number of Participants With Unsolicited Adverse Events and 1 more. Started May 2023; status: completed.
02
Drugs
mRNA-1010
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05868382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05868382.